How to buy NovoCure stock

NovoCure Limited is a medical instruments & supplies business based in the US. NovoCure shares (NVCR) are listed on the NASDAQ and all prices are listed in US Dollars. NovoCure employs 1,023 staff and has a trailing 12-month revenue of around 0.00.

NovoCure share price

Use our graph to track the performance of NVCR stocks over time.

NovoCure shares at a glance

• Key figures

Information last updated 2021-03-10.

52-week range	$53.40 - $194.75
50-day moving average	$165.96
200-day moving average	$138.21
Wall St. target price	$154.88
PE ratio	731.1112
Dividend yield	N/A (0%)
Earnings per share (TTM)	$0.18

Buy NovoCure shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy NovoCure stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of NovoCure Limited by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is NovoCure under- or over-valued?

Valuing NovoCure stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of NovoCure's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

NovoCure's P/E ratio

NovoCure's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 731x. In other words, NovoCure shares trade at around 731x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

NovoCure's EBITDA

NovoCure's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $38.6 million.

The EBITDA is a measure of a NovoCure's overall financial performance and is widely used to measure a its profitability.

NovoCure financials

Revenue TTM	$494.4 million
Operating margin TTM	6.23%
Gross profit TTM	$388.3 million
Return on assets TTM	2.52%
Return on equity TTM	5.71%
Profit margin	4.01%
Book value	$4.66
Market capitalisation	$13.5 billion

TTM: trailing 12 months

Shorting NovoCure shares

There are currently 4.6 million NovoCure shares held short by investors – that's known as NovoCure's "short interest". This figure is 0.7% down from 4.6 million last month.

There are a few different ways that this level of interest in shorting NovoCure shares can be evaluated.

NovoCure's "short interest ratio" (SIR)

NovoCure's "short interest ratio" (SIR) is the quantity of NovoCure shares currently shorted divided by the average quantity of NovoCure shares traded daily (recently around 697783.48484848). NovoCure's SIR currently stands at 6.6. In other words for every 100,000 NovoCure shares traded daily on the market, roughly 6600 shares are currently held short.

However NovoCure's short interest can also be evaluated against the total number of NovoCure shares, or, against the total number of tradable NovoCure shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NovoCure's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 NovoCure shares in existence, roughly 50 shares are currently held short) or 0.0518% of the tradable shares (for every 100,000 tradable NovoCure shares, roughly 52 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against NovoCure.

Find out more about how you can short NovoCure stock.

NovoCure share dividends

We're not expecting NovoCure to pay a dividend over the next 12 months.

NovoCure share price volatility

Over the last 12 months, NovoCure's shares have ranged in value from as little as $53.4 up to $194.75. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NovoCure's is 1.0352. This would suggest that NovoCure's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

NovoCure overview

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. It has a clinical trial collaboration agreement with MSD to evaluate tumor treating fields together with KEYTRUDA, an anti-PD-1 therapy; and a strategic alliance with the NYU Grossman School of Medicine's Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey. .

Frequently asked questions

• What percentage of NovoCure is owned by insiders or institutions?

  Currently 14.821% of NovoCure shares are held by insiders and 82.912% by institutions.

• How many people work for NovoCure?

  Latest data suggests 1,023 work at NovoCure.

• When does the fiscal year end for NovoCure?

  NovoCure's fiscal year ends in December.

• Where is NovoCure based?

  NovoCure's address is: No. 4 The Forum, Saint Helier, Jersey, JE2 4UF

• What is NovoCure's ISIN number?

  NovoCure's international securities identification number is: JE00BYSS4X48

• What is NovoCure's CUSIP number?

  NovoCure's Committee on Uniform Securities Identification Procedures number is: G6674U108